Key Points
- CFO Oluyemi Okupe sold 36,922 shares on April 16 at $25.90 (≈$956,279.80) and, together with an April 17 sale, sold about 54,927 shares (~$1.46M) under a pre‑arranged Rule 10b5‑1 plan, trimming his stake by ~11.6% to 281,867 shares valued at ≈$7.3M.
- Q1 results beat expectations: Hims & Hers reported $0.08 EPS versus $0.02 expected and revenue of $617.8M (up 28.4% YoY), while the stock has rallied (opened $31.01, up 7.6%) and the company has a market cap of about $7.07B.
- Analyst consensus is a "Hold" with an average price target of $31.86 after several firms cut targets (e.g., Morgan Stanley, Truist), and institutional investors own roughly 63.5% of the stock.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 18,005 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15. Following the transaction, the chief financial officer directly owned 270,046 shares in the company, valued at $7,515,380.18. The trade was a 6.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80.
- On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total value of $79,420.50.
- On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
- On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.
Hims & Hers Health Price Performance
Shares of NYSE:HIMS opened at $31.01 on Tuesday. The company has a market cap of $7.07 billion, a P/E ratio of 60.80, a P/E/G ratio of 2.74 and a beta of 2.32. The business has a fifty day simple moving average of $19.95 and a 200-day simple moving average of $31.92. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same period in the prior year, the business posted $0.11 earnings per share. The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.61 EPS for the current year.
Key Hims & Hers Health News
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Investor momentum: Traders are buying HIMS on optimism about its peptide drug pipeline and reports of a potential deal with Novo Nordisk, which, coupled with an upcoming May 11 earnings report, is cited as the main catalyst for the rally. Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
- Neutral Sentiment: Biotech sector news: Positive clinical data at peers (e.g., Nektar’s alopecia results) is lifting sentiment across small-cap biopharma stocks; this sector-wide risk-on tone may be contributing to flows into HIMS even if the news isn’t company-specific. This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness.
- Neutral Sentiment: Short-interest update: A recent short-interest note was published; changes in short interest can amplify moves into earnings but the update itself doesn’t clearly favor one direction. Monitor short-interest levels for potential squeeze risk. Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update
- Negative Sentiment: Insider sales: CFO Oluyemi Okupe sold a block of shares on Apr 16–17 (total ~54,927 shares) under a pre‑arranged Rule 10b5‑1 plan — roughly $1.46M at the reported prices — reducing his stake. The sales are disclosed in an SEC Form 4 filing; because they were executed under a 10b5‑1 plan the signal is muted but still a short‑term caution for sentiment. SEC Form 4 - Insider Sale
Analyst Ratings Changes
A number of brokerages have weighed in on HIMS. Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $25.00 and gave the company a "neutral" rating in a report on Thursday, April 16th. Truist Financial reiterated a "hold" rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Morgan Stanley cut their price target on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 24th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a "market perform" rating in a report on Monday, March 16th. Finally, Citigroup upgraded Hims & Hers Health from a "sell" rating to a "neutral" rating and boosted their price target for the company from $13.25 to $24.00 in a report on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $31.86.
Read Our Latest Analysis on Hims & Hers Health
Institutional Investors Weigh In On Hims & Hers Health
Several large investors have recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock worth $1,452,000 after purchasing an additional 200 shares in the last quarter. GAMMA Investing LLC lifted its position in Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock worth $232,000 after buying an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC raised its holdings in shares of Hims & Hers Health by 1.8% during the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock worth $793,000 after acquiring an additional 252 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company's stock valued at $54,000 after buying an additional 283 shares during the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co lifted its stake in Hims & Hers Health by 4.8% in the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company's stock valued at $436,000 after acquiring an additional 350 shares during the last quarter. 63.52% of the stock is owned by institutional investors.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
